Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 4/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375154 | 0.82 | F10 (0.55) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6374167 | 0.82 | F10 (0.64) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6374177 | 0.82 | F10 (0.64) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6379420 | 0.77 | F10 (0.52) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6374977 | 0.77 | F10 (0.52) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6374974 | 0.77 | F10 (0.52) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6375140 | 0.76 | USP30 (0.56) | F10FPR2USP30 | |
| SCHEMBL6381183 | 0.76 | USP30 (0.56) | F10FPR2USP30 | |
| SCHEMBL7088998 | 0.74 | MAPK1 (0.51) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6378918 | 0.73 | F10 (0.53) | CA12CA1CA2CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | claimed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | CA12 1466/4885CA1 1340/4885CA2 2319/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | CA12 879/4885CA1 1367/4885CA2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.